Results 51 to 60 of about 180 (117)

A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update

Therapeutic Advances in Neurological Disorders
Background: Cladribine tablets are contraindicated during pregnancy; therefore, safety data on pregnancies exposed to this treatment are limited. CLEAR collects and describes pregnancy outcomes in this understudied population. Objectives: To describe the
Kerstin Hellwig, Melinda Magyari, Thomas M. MacDonald, Carolyn E. Cesta, Stig Wergeland, Maarit K. Leinonen, Asher Ornoy, Sandra Vukusic, Alexandra Lauer, Xiaolei Zhou, Alison Kawai, Rachel Weinrib, Alejandro Arana, Tahani Boumenna   +13 more
doaj   +1 more source

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands [PDF]

Applied Health Economics and Health Policy, 2019
Cladribine tablets have recently become available in The Netherlands for patients with relapsing-remitting multiple sclerosis (RRMS) as a disease-modifying agent that reduces the frequency and severity of relapses and delays disability progression.The aim of this study was to evaluate the cost effectiveness of cladribine tablets, compared with ...
Renée Else Michels, Maria de Fransesco, Koshu Mahajan, Gerald J. D. Hengstman, Krijn M. H. Schiffers, Sangeeta Budhia, Gerard Harty, Marieke Krol   +7 more
openaire   +2 more sources

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +2 more sources

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +2 more sources

Effect of Cladribine Tablets on the Pharmacokinetics of a Combined Oral Contraceptive in Pre‐Menopausal Women With Relapsing Multiple Sclerosis

Clinical and Translational Science, Volume 18, Issue 4, April 2025.
ABSTRACT This study assessed the effect of cladribine tablets (CladT) on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in pre‐menopausal women with relapsing multiple sclerosis. It was a randomized, double‐blind, two‐period, two‐sequence crossover study to assess steady‐state plasma PK (area under the concentration–time curve and ...
Robert Hermann, Kerstin Hellwig, Sumedh Gaikwad, Andrew Galazka, Afrim Bytyqi, Dominic Jack, Axel Krebs‐Brown, Claudia Vetter, Axel Nolting, Karthik Venkatakrishnan, Jennifer Q. Dong   +10 more
wiley   +1 more source

Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists

European Journal of Neurology, Volume 32, Issue 4, April 2025.
ABSTRACT Background Multiple sclerosis (MS) places substantial socioeconomic burden on patients due to its early onset and progressive nature, but healthcare systems are also impacted by the high costs of disease‐modifying treatments (DMTs). The use of generics (for conventional drugs), biosimilars (for biologics) or follow‐on versions of non‐biologic ...
Thomas Berger, Markus Zeitlinger, Veronica Popescu, Melinda Magyari, Laura Airas, Mona Alkhawajah, Maura Pugliatti, Magd Zakaria, Carlo Pozzilli, Jelena Drulovic, Bart Van Wijmeersch, Patrick Vermersch, Celia Oreja‐Guevara   +12 more
wiley   +1 more source

Possible Reasons for the Suboptimal Response of the Cladribine Course in Daily Practice: An Independent Analysis of Data from 12 Russian Clinics and the Results of Post-Registration Studies in Other Countries

Sclerosis
Objectives: The purpose of this study was to analyze the effect of daily intake of cladribine tablets on the course of multiple sclerosis (MS) while monitoring for 1–4 years during and after the course in several neurological clinics from different ...
Alexey N. Boyko, Valentina M. Alifirova, Daria V. Pashkovskaya, Ekaterina I. Kuchina, Stella A. Sivertseva, Elena L. Turova, Zoya A. Goncharova, Olga Yu Rudenko, Yulia Yu Pogrebnova, Farid A. Khabirov, Timur I. Khaibullin, Natalia N. Babicheva, Natalia L. Khoroshilova, Oksana V. Dzundza, Olga A. Soldatova, Anna N. Belova, Gennadyi E. Sheiko, Anastasia E. Makarova, Natalia G. Glavinskaya   +18 more
doaj   +1 more source

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets

Therapeutics and Clinical Risk Management, 2010
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) that represents one of the first causes of neurological disability in young adults. Although the pathogenesis of MS is still unclear, an autoimmune mechanism has been demonstrated. According to this evidence in the last 15 years different treatments acting on
POZZILLI, Carlo, GASPERINI, claudio, RUGGIERI, SERENA   +2 more
openaire   +5 more sources

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +2 more sources

Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis in Italy

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a chronic autoimmune disease impacting the central nervous system. Individuals with highly active relapsing–remitting MS (HA-RRMS) frequently experience symptomatic episodes lasting more than 24 h, followed by a ...
Barbara Polistena, Anna Maria Provenzano, Caterina Rizzi, Elena Colombo, Roberto Bergamaschi   +4 more
doaj   +1 more source